Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.37 |
| ▸ | TEK | Q02763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24216208 | 0.98 | HDAC6 (0.41) | HDAC6LRRK2HDAC1KDREPHB4 | |
| SCHEMBL25349538 | 0.94 | HDAC6 (0.40) | HDAC6LRRK2KDREPHB4TEK | |
| SCHEMBL25356167 | 0.88 | LRRK2 (0.42) | HDAC6LRRK2HDAC1 | |
| SCHEMBL25350086 | 0.87 | LRRK2 (0.41) | HDAC6LRRK2HDAC1 | |
| SCHEMBL25349517 | 0.87 | HDAC1 (0.45) | HDAC6LRRK2HDAC1 | |
| SCHEMBL24217084 | 0.86 | LRRK2 (0.42) | HDAC6LRRK2HDAC1 | |
| SCHEMBL30409371 | 0.86 | LRRK2 (0.42) | HDAC6LRRK2HDAC1 | |
| SCHEMBL25348179 | 0.86 | HDAC6 (0.41) | HDAC6LRRK2HDAC1 | |
| SCHEMBL24216144 | 0.85 | HDAC6 (0.48) | HDAC6HDAC1KDREPHB4TEK | |
| SCHEMBL30460258 | 0.85 | HDAC6 (0.48) | HDAC6HDAC1KDREPHB4TEK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257372-A1 | NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | HDAC6, HDAC1, HDAC3 | HDAC6 1/4885LRRK2 1788/4885HDAC1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.